NASDAQ:AERI
Delisted
Aerie Pharmaceuticals Stock News
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
06:30am, Monday, 20'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
06:30am, Monday, 13'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
07:30am, Tuesday, 07'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
07:30am, Thursday, 12'th Aug 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q2 2021 Results - Earnings Call Transcript
11:54pm, Wednesday, 04'th Aug 2021
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q2 2021 Results - Earnings Call Transcript
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
06:19pm, Wednesday, 04'th Aug 2021
Aerie (AERI) delivered earnings and revenue surprises of -3.08% and 2.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
06:30am, Thursday, 15'th Jul 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
06:45am, Monday, 21'st Jun 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
06:30am, Thursday, 17'th Jun 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
02:16pm, Thursday, 06'th May 2021
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript
12:05am, Thursday, 06'th May 2021
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
07:10pm, Wednesday, 05'th May 2021
Aerie (AERI) delivered earnings and revenue surprises of -4.35% and -1.64%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Aerie (AERI) This Earnings Season?
10:32am, Tuesday, 04'th May 2021
Aerie (AERI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
